Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Vis Exp ; (147)2019 05 21.
Article in English | MEDLINE | ID: mdl-31180351

ABSTRACT

MicroRNAs (miRNAs) are small regulatory RNAs which are recognized to modulate numerous intracellular signaling pathways in several diseases including cancers. These small regulatory RNAs mainly interact with the 3' untranslated regions (3' UTR) of their target messenger RNAs (mRNAs) ultimately resulting in the inhibition of decoding processes of mRNAs and the augmentation of target mRNA degradations. Based on the expression levels and intracellular functions, miRNAs are able to serve as regulatory factors of oncogenic and tumor-suppressive mRNAs. Identification of bona fide target genes of a miRNA among hundreds or even thousands of computationally predicted targets is a crucial step to discern the roles and basic molecular mechanisms of a miRNA of interest. Various miRNA target prediction programs are available to search possible miRNA-mRNA interactions. However, the most challenging question is how to validate direct target genes of a miRNA of interest. This protocol describes a reproducible strategy of key methods on how to identify miRNA targets related to the function of a miRNA. This protocol presents a practical guide on step-by-step procedures to uncover miRNA levels, functions, and related target mRNAs using the probe-based real-time polymerase chain reaction (PCR), sulforhodamine B (SRB) assay following a miRNA mimic transfection, dose-response curve generation, and luciferase assay along with the cloning of 3' UTR of a gene, which is necessary for proper understanding of the roles of individual miRNAs.


Subject(s)
Genes, Neoplasm , MicroRNAs/metabolism , Neoplasms/genetics , 3' Untranslated Regions/genetics , Cell Line, Tumor , Gene Expression Regulation, Neoplastic , Humans , Luciferases/genetics , MicroRNAs/genetics , RNA, Messenger/genetics
2.
Anticancer Res ; 38(11): 6309-6316, 2018 Nov.
Article in English | MEDLINE | ID: mdl-30396951

ABSTRACT

BACKGROUND/AIM: Patients with advanced non-small cell lung cancer (NSCLC) frequently face a dismal prognosis because of lack of curative therapies. We, therefore, conducted a preclinical investigation of the therapeutic efficacy of microRNA-107 (miR-107). MATERIALS AND METHODS: The effects of miR-107 on cell proliferation and target gene expression were studied. Combinatorial effects of miR-107 and parthenolide were evaluated. RESULTS: Cell proliferation was repressed in A549 NSCLC cells transfected with miR-107. Inhibitor of nuclear factor kappa B kinase subunit gamma was directly targeted by miR-107. Overexpression of miR-107 in A549 cells sensitized them to parthenolide along with a marked reduction of cyclin-dependent kinase 2. CONCLUSION: Our findings unveil an important biological function of miR-107 in regulating lung cancer cell proliferation and elevating an antiproliferative effect of parthenolide on lung cancer cells, suggesting that miR-107 could be beneficial benefit treatment for advanced NSCLC.


Subject(s)
Carcinoma, Non-Small-Cell Lung/genetics , I-kappa B Kinase/genetics , Lung Neoplasms/genetics , MicroRNAs/genetics , Sesquiterpenes/pharmacology , 3' Untranslated Regions , A549 Cells , Binding Sites , Cell Movement/drug effects , Cell Proliferation/drug effects , Cell Survival/drug effects , Computational Biology , Gene Expression Regulation, Neoplastic/drug effects , Humans , I-kappa B Kinase/chemistry
SELECTION OF CITATIONS
SEARCH DETAIL
...